Found: 21
Select item for more details and to access through your institution.
Cell‐free DNA analysis for detection of MYD88<sup>L265P</sup> and CXCR4<sup>S338X</sup> mutations in Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E250, doi. 10.1002/ajh.26184
- By:
- Publication type:
- Article
CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. E95, doi. 10.1002/ajh.25730
- By:
- Publication type:
- Article
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 4, p. 372, doi. 10.1002/ajh.25712
- By:
- Publication type:
- Article
Mutated MYD88 regulates transcription of the pro-survival kinase HCK in MYD88 driven B-cell lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e338, doi. 10.1016/j.clml.2019.09.557
- By:
- Publication type:
- Article
The BCR component SYK is activated by mutated MYD88 and the combined inhibition of SYK and BTK produces synthetic lethality in MYD88 driven B-cell lymphomas.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e338, doi. 10.1016/j.clml.2019.09.556
- By:
- Publication type:
- Article
Distribution of circulating tumor cells in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e337, doi. 10.1016/j.clml.2019.09.554
- By:
- Publication type:
- Article
Dysregulation of the B-Cell Receptor Pathway Through Alternative Splicing in Waldenstrom's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e335, doi. 10.1016/j.clml.2019.09.550
- By:
- Publication type:
- Article
MYD88 and CXCR4 Mutation Rates by Allele-Specific PCR Compared with Diagnostic Next Generation Sequencing Panels in Patients with Waldenstrom's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e317, doi. 10.1016/j.clml.2019.09.521
- By:
- Publication type:
- Article
CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e316, doi. 10.1016/j.clml.2019.09.520
- By:
- Publication type:
- Article
Insights into the Genomic Evolution of Ibrutinib Resistant Clones in Waldenström's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e319, doi. 10.1016/j.clml.2019.09.524
- By:
- Publication type:
- Article
Cell-Free DNA as Alternative to Bone Marrow CD19+ Selection for Diagnostic MYD88 L265P in Waldenstrom's Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e311, doi. 10.1016/j.clml.2019.09.511
- By:
- Publication type:
- Article
Identifying regulatory mutational densities within Waldenstrom's Macroglobulinemia by whole genome sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e307, doi. 10.1016/j.clml.2019.09.504
- By:
- Publication type:
- Article
Impact of Chromosome 6q Deletions in Multiple Myeloma and Waldenström's Macroglobulinemia by Next Generation RNA Sequencing.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e39, doi. 10.1016/j.clml.2019.09.059
- By:
- Publication type:
- Article
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41408-020-0277-6
- By:
- Publication type:
- Article
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next‐generation sequencing in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 730, doi. 10.1111/bjh.17385
- By:
- Publication type:
- Article
Partial response or better at six months is prognostic of superior progression‐free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 3, p. 542, doi. 10.1111/bjh.17225
- By:
- Publication type:
- Article
Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 6, p. 1165, doi. 10.1111/bjh.16463
- By:
- Publication type:
- Article
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 356, doi. 10.1111/bjh.16088
- By:
- Publication type:
- Article
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 2, p. 242, doi. 10.1111/bjh.15560
- By:
- Publication type:
- Article
<italic>MYD88</italic> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
- Published in:
- British Journal of Haematology, 2018, v. 180, n. 3, p. 374, doi. 10.1111/bjh.15049
- By:
- Publication type:
- Article
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation.
- Published in:
- Cancers, 2024, v. 16, n. 6, p. 1116, doi. 10.3390/cancers16061116
- By:
- Publication type:
- Article